person · Reporting owner
Pellizzari Christine A
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSMED IncINSM · Entity 3174 | Chief Legal Officer | May 15, 2021 | May 18, 2021 |
| Imunon, Inc.IMNN · Entity 8041 | Director | July 31, 2026 | August 04, 2026 |
| NeuroSense Therapeutics Ltd.NRSN · Entity 7767 | Director | March 18, 2026 | March 18, 2026 |
| Tempest Therapeutics, Inc.TPST · Entity 7734 | Director | January 27, 2026 | January 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSMED Inc
Report date May 15, 2021 · Filed May 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 149,985 |
Reported balance
After 2021-05-15 transaction · row 1
1 source rowRow 1 · 2021-05-15 · Tax withholding · Disposed 2,546 · Balance 149,985 F1: Shares withheld by the Company to satisfy tax withholding requirements on vesting of time-based restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Company to satisfy tax withholding requirements on vesting of time-based restricted stock units.
Imunon, Inc.
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,076 |
Reported balance
After 2026-07-31 transaction · row 1
1 source rowRow 1 · 2026-07-31 · Grant · Acquired 6,934 · Balance 15,076 F1: Stock granted in lieu of cash for portion of board fees |
Filing footnotes · ownership attribution and instrument terms
F1: Stock granted in lieu of cash for portion of board fees
NeuroSense Therapeutics Ltd.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 48,000 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 48,000 |
| Ordinary SharesSEC Table I · non-derivative | Direct | 60,000 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 60,000 F1: These restricted shares vest on December 30, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 99,898 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 99,898 F2: These restricted shares vest on January 30, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person. |
| Options to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $1.43 · Expires 2032-03-10 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: These options are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted shares vest on December 30, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
F2: These restricted shares vest on January 30, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
F3: These options are fully vested and exercisable.
Tempest Therapeutics, Inc.
Report date January 27, 2026 · Filed January 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2036-01-26 | Direct | 1,230 |
Reported balance
After 2026-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-27 · Grant · Acquired 1,230 · Balance 1,230 F1: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Science 37 Holdings, Inc.
Report date March 12, 2024 · Filed March 12, 2024
Section 16 reporting ended · disclosed 2024-03-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-12 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-03-12 · Other · Disposed 14,579 · Balance 0 F1: Includes 125 shares acquired under the issuer's Employee Stock Purchase Plan and includes 78 shares that were inadvertently omitted from holdings on the Reporting Person's prior Form 4. F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 28, 2024, among the Issuer, eMed, LLC, a Delaware limited liability company ("Parent"), and Marlin Merger Sub Corporation, a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer ("Issuer Common Stock") at a purchase price of $5.75 per share, without interest and subject to applicable withholding taxes (the "Offer Price"). After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of March 12, 2024 (such date and time of such merger, the "Effective Time"). These shares of Issuer Common Stock were tendered for purchase pursuant to the tender offer. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-12 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-03-12 · Disposition to issuer · Disposed 35,115 · Balance 0 F3: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Issuer Common Stock upon vesting of the RSU. F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Issuer Common Stock subject to such RSU. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-12 · Disposition to issuer · Disposed 37,222 · Balance 0 F3: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Issuer Common Stock upon vesting of the RSU. F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Issuer Common Stock subject to such RSU. |
| Earn-Out RightSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-12 · Disposition to issuer · Disposed 428 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, all "Earn-Out Rights" (that is, all rights to receive Issuer Common Stock that were reserved for issuance as "Earn-Out Shares" pursuant to, and under the circumstances set forth in, Section 2.8 of the Agreement and Plan of Merger dated as of May 6, 2021 by and among the Issuer, LifeSci Acquisition II Corp. and LifeSci Acquisition II Merger Sub, Inc.) that were outstanding immediately prior to the Effective Time automatically were cancelled and ceased to exist at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 125 shares acquired under the issuer's Employee Stock Purchase Plan and includes 78 shares that were inadvertently omitted from holdings on the Reporting Person's prior Form 4.
F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 28, 2024, among the Issuer, eMed, LLC, a Delaware limited liability company ("Parent"), and Marlin Merger Sub Corporation, a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer ("Issuer Common Stock") at a purchase price of $5.75 per share, without interest and subject to applicable withholding taxes (the "Offer Price"). After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of March 12, 2024 (such date and time of such merger, the "Effective Time"). These shares of Issuer Common Stock were tendered for purchase pursuant to the tender offer.
F3: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Issuer Common Stock upon vesting of the RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Issuer Common Stock subject to such RSU.
F5: Pursuant to the Merger Agreement, at the Effective Time, all "Earn-Out Rights" (that is, all rights to receive Issuer Common Stock that were reserved for issuance as "Earn-Out Shares" pursuant to, and under the circumstances set forth in, Section 2.8 of the Agreement and Plan of Merger dated as of May 6, 2021 by and among the Issuer, LifeSci Acquisition II Corp. and LifeSci Acquisition II Merger Sub, Inc.) that were outstanding immediately prior to the Effective Time automatically were cancelled and ceased to exist at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2021 Filed Jan 27, 2021 21:17 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,600 | $44.04 | $114,504.00 |
DisclosureSEC source: 0001104659-21-008179 · tm213966-2_4seq1.xml · nonDerivative · entry 6 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,721 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 2,600 shares sold at prices ranging from $43.75 to $44.23 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 21:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 2,600 | $10.85 | $28,210.00 |
DisclosureSEC source: 0001104659-21-008179 · tm213966-2_4seq1.xml · nonDerivative · entry 5 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001104659-21-008179 · tm213966-2_4seq1.xml · derivative · entry 8 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,150 Underlying: Common Stock · 6,000 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each six-month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001104659-21-008179 · tm213966-2_4seq1.xml · derivative · entry 7 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,150 Underlying: Common Stock · 15,000 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each six-month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:17 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 6,000 | $43.84 | $263,040.00 |
DisclosureSEC source: 0001104659-21-008179 · tm213966-2_4seq1.xml · nonDerivative · entry 4 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,721 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 6,000 shares sold at prices ranging from $43.75 to $43.94 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,000 | $10.85 | $65,100.00 |
DisclosureSEC source: 0001104659-21-008179 · tm213966-2_4seq1.xml · nonDerivative · entry 3 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:17 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 15,000 | $42.95 | $644,250.00 |
DisclosureSEC source: 0001104659-21-008179 · tm213966-2_4seq1.xml · nonDerivative · entry 2 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,721 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 15,000 shares sold at prices ranging from $42.75 to $43.58 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 15,000 | $10.85 | $162,750.00 |
DisclosureSEC source: 0001104659-21-008179 · tm213966-2_4seq1.xml · nonDerivative · entry 1 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:49 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001104659-21-006698 · tm213966-1_4seq1.xml · derivative · entry 9 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,150 Underlying: Common Stock · 10,000 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:49 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001104659-21-006698 · tm213966-1_4seq1.xml · derivative · entry 8 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,150 Underlying: Common Stock · 10,000 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:49 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 10,000 | $41.98 | $419,800.00 |
DisclosureSEC source: 0001104659-21-006698 · tm213966-1_4seq1.xml · nonDerivative · entry 6 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,721 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 10,000 shares sold at prices ranging from $41.75 to $42.19 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:49 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 10,000 | $10.85 | $108,500.00 |
DisclosureSEC source: 0001104659-21-006698 · tm213966-1_4seq1.xml · nonDerivative · entry 5 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:49 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 10,000 | $41.05 | $410,500.00 |
DisclosureSEC source: 0001104659-21-006698 · tm213966-1_4seq1.xml · nonDerivative · entry 4 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,721 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 10,000 shares sold at prices ranging from $40.75 to $41.60 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:49 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 10,000 | $10.85 | $108,500.00 |
DisclosureSEC source: 0001104659-21-006698 · tm213966-1_4seq1.xml · nonDerivative · entry 3 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:49 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001104659-21-006698 · tm213966-1_4seq1.xml · derivative · entry 7 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,150 Underlying: Common Stock · 10,000 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:49 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 10,000 | $39.87 | $398,700.00 |
DisclosureSEC source: 0001104659-21-006698 · tm213966-1_4seq1.xml · nonDerivative · entry 2 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,721 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 10,000 shares sold at prices ranging from $39.75 to $40.08 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:49 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 10,000 | $10.85 | $108,500.00 |
DisclosureSEC source: 0001104659-21-006698 · tm213966-1_4seq1.xml · nonDerivative · entry 1 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 21:38 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 45,600 | $0.00 Strike: $34.03 | $0.00 |
DisclosureSEC source: 0001104659-21-002508 · tm211774-10_4seq1.xml · derivative · entry 2 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,600 Underlying: Common Stock · 45,600 shares Expires 2031-01-07 F3 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 21:38 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 9,183 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-002508 · tm211774-10_4seq1.xml · nonDerivative · entry 1 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,721 F1 · shares: Restricted stock units granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on January 7, 2021, for no consideration, and represents a contingent right to receive one share of Common Stock. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:12 UTC | INSMED Inc INSM · Entity 3174 | Tax withholdingCommon Stock | 650 | $33.42 | $21,723.00 |
DisclosureSEC source: 0001104659-21-001604 · tm211774d3_4seq1.xml · nonDerivative · entry 2 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,538 F1 · shares: Shares withheld by the Company to satisfy tax withholding requirements on vesting of time-based restricted stock units. Read SEC document |
| January 03, 2021 Filed Jan 6, 2021 22:12 UTC | INSMED Inc INSM · Entity 3174 | Tax withholdingCommon Stock | 1,814 | $33.29 | $60,388.06 |
DisclosureSEC source: 0001104659-21-001604 · tm211774d3_4seq1.xml · nonDerivative · entry 1 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,188 F1 · shares: Shares withheld by the Company to satisfy tax withholding requirements on vesting of time-based restricted stock units. Read SEC document |
| November 05, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $20.49 | $0.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · derivative · entry 38 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2024-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| November 05, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 35,904 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · derivative · entry 37 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,904 shares Expires 2023-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| November 05, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 3,750 | $20.49 | $76,837.50 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · nonDerivative · entry 25 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 35,904 | $11.14 | $399,970.56 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · nonDerivative · entry 24 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 15,665 | $0.00 Strike: $12.58 | $0.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · derivative · entry 36 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,665 shares Expires 2024-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 2,024 | $0.00 Strike: $12.58 | $0.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · derivative · entry 35 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,665 Underlying: Common Stock · 2,024 shares Expires 2024-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 12,311 | $0.00 Strike: $12.58 | $0.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · derivative · entry 34 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,689 Underlying: Common Stock · 12,311 shares Expires 2024-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 15,665 | $34.38 | $538,562.70 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · nonDerivative · entry 23 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,348 F11 · price: This is the weighted average sales price representing 15,665 shares sold at prices ranging from $34.28 to $34.49 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 15,665 | $12.58 | $197,065.70 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · nonDerivative · entry 22 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,024 | $34.55 | $69,929.20 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · nonDerivative · entry 21 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,348 F10 · price: This is the weighted average sales price representing 2,024 shares sold at prices ranging from $34.50 to $34.62 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 2,024 | $12.58 | $25,461.92 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · nonDerivative · entry 20 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 12,311 | $34.10 | $419,805.10 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · nonDerivative · entry 19 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,348 F9 · price: This is the weighted average sales price representing 12,311 shares sold at prices ranging from $34.00 to $34.28 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 12,311 | $12.58 | $154,872.38 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · nonDerivative · entry 18 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 38,696 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · derivative · entry 33 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,696 shares Expires 2023-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 400 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · derivative · entry 32 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,696 Underlying: Common Stock · 400 shares Expires 2023-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · derivative · entry 31 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,096 Underlying: Common Stock · 25,000 shares Expires 2023-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 11,317 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · derivative · entry 30 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,096 Underlying: Common Stock · 11,317 shares Expires 2023-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · derivative · entry 29 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,413 Underlying: Common Stock · 1,000 shares Expires 2023-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 14,351 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · derivative · entry 28 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,413 Underlying: Common Stock · 14,351 shares Expires 2023-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 10,649 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · derivative · entry 27 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,764 Underlying: Common Stock · 10,649 shares Expires 2023-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 12,683 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · derivative · entry 26 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,413 Underlying: Common Stock · 12,683 shares Expires 2023-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 38,396 | $32.95 | $1,265,148.20 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · nonDerivative · entry 17 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,348 F8 · price: This is the weighted average sales price representing 38,696 shares sold at prices ranging from $32.81 to $33.09 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 38,396 | $11.14 | $427,731.44 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · nonDerivative · entry 16 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 400 | $33.10 | $13,240.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · nonDerivative · entry 15 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,348 Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 400 | $11.14 | $4,456.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · nonDerivative · entry 14 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 25,000 | $32.32 | $808,000.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · nonDerivative · entry 13 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,348 F7 · price: This is the weighted average sales price representing 25,000 shares sold at prices ranging from $32.25 to $32.45 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 25,000 | $11.14 | $278,500.00 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · nonDerivative · entry 12 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 11,317 | $31.87 | $360,672.79 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · nonDerivative · entry 11 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,348 F6 · price: This is the weighted average sales price representing 11,317 shares sold at prices ranging from $31.75 to $32.00 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 23:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 11,317 | $11.14 | $126,071.38 |
DisclosureSEC source: 0001104659-20-121948 · a4.xml · nonDerivative · entry 10 Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.